A comprehensive survival analysis using the TCGA database revealed that glioma patients with elevated STAT3 expression had reduced overall survival, progress free interval, and disease specific survival compared to those with expressed lower levels of STAT3 (p < 0.001, Figures 3B–D). The gene discussed is STAT3; the disease is central nervous system cancer.